Navigation Links
Obesity research boosted by watching hunger in the brain
Date:11/7/2007

ery little about the mechanisms behind these processes and why they can vary so much between individuals. In the past we have had to rely on asking people how hungry they feel, this can be very subjective. Furthermore, sometimes your sense of satiety can be significantly affected by other factors such as your mood.

Our new method is much more reliable and completely objective. With murine models, we can now look directly at neuronal activity in the brain. We are working on developing similar methods to study neuronal activity in the appetite centers in people, he added.

For the study, mice given the contrast agent were also given one of two types of hormone. These were either pancreatic peptide YY (PYY), which is known to inhibit appetite, or ghrelin, which is known to increase it. The scientists then monitored the reactions of the hunger neurons to these stimuli. As expected, the intensity of the neurons signals increased when ghrelin was administered and decreased with PYY.


'/>"/>

Contact: Laura Gallagher
L.Gallagher@imperial.ac.uk
44-020-759-46702
Imperial College London
Source:Eurekalert

0

GOOD

Page: 1 2

Related medicine news :

1. Virus Could Help Drive Obesity
2. Surgery for severe obesity saves lives
3. Obesity Doesnt Always Equal Diabetes
4. Obesity Rate in U.S. Still Climbing
5. Treating diabetes during pregnancy can break link to childhood obesity
6. ZIP codes and property values predict obesity rates
7. High and mighty: first common height gene identified by researchers behind obesity gene finding
8. Research Links TV/Video Game Playing With Child Obesity; Health Experts Back a New Approach
9. UT Southwesterns obesity research receives $22 million NIH Roadmap grant
10. Genaera Announces Formation of Scientific Advisory Board for Obesity Drug Candidate Trodusquemine (MSI-1436)
11. Cities Say Restaurant Nutrition Information Crucial in Fighting Obesity
Post Your Comments:
*Name:
*Comment:
*Email:
Other Medicine News:Health News:Reed Smith to Merge with Richards Butler Hong Kong 2Health News:Reed Smith to Merge with Richards Butler Hong Kong 3Health News:Reed Smith to Merge with Richards Butler Hong Kong 4Health News:The politics of the playground: lack of athletic skill often means loneliness and peer rejection 2Health News:MDS Nordion signs 17-year contract with Rosenergoatom 2Health News:UP Repeats NCQA Certification in Utilization Management 2Health News:Uroplasty, Inc. Announces Filing of Registration Statement for Offering of Common Stock 2Health News:Uroplasty, Inc. Announces Filing of Registration Statement for Offering of Common Stock 3Health News:Kensey Nash Reports First Quarter Fiscal Year 2008 Results 2Health News:Kensey Nash Reports First Quarter Fiscal Year 2008 Results 3Health News:Kensey Nash Reports First Quarter Fiscal Year 2008 Results 4Health News:Kensey Nash Reports First Quarter Fiscal Year 2008 Results 5Health News:Kensey Nash Reports First Quarter Fiscal Year 2008 Results 6Health News:Kensey Nash Reports First Quarter Fiscal Year 2008 Results 7Health News:Kensey Nash Reports First Quarter Fiscal Year 2008 Results 8Health News:Kensey Nash Reports First Quarter Fiscal Year 2008 Results 9Health News:Kensey Nash Reports First Quarter Fiscal Year 2008 Results 10Health News:Kensey Nash Reports First Quarter Fiscal Year 2008 Results 11Health News:Kensey Nash Reports First Quarter Fiscal Year 2008 Results 12Health News:Kensey Nash Reports First Quarter Fiscal Year 2008 Results 13Health News:Kensey Nash Reports First Quarter Fiscal Year 2008 Results 14
Breaking Medicine Technology:Within3 Expands into Mobile Applications 2Phase III CONFIRM Study Shows FASLODEX(R) (fulvestrant) Injection 500 mg May Delay Time of Disease Progression Over 250-mg Dose in Postmenopausal Women With Hormone Receptor-Positive Advanced Breast Cancer 2Phase III CONFIRM Study Shows FASLODEX(R) (fulvestrant) Injection 500 mg May Delay Time of Disease Progression Over 250-mg Dose in Postmenopausal Women With Hormone Receptor-Positive Advanced Breast Cancer 3Phase III CONFIRM Study Shows FASLODEX(R) (fulvestrant) Injection 500 mg May Delay Time of Disease Progression Over 250-mg Dose in Postmenopausal Women With Hormone Receptor-Positive Advanced Breast Cancer 4Phase III CONFIRM Study Shows FASLODEX(R) (fulvestrant) Injection 500 mg May Delay Time of Disease Progression Over 250-mg Dose in Postmenopausal Women With Hormone Receptor-Positive Advanced Breast Cancer 5Phase III CONFIRM Study Shows FASLODEX(R) (fulvestrant) Injection 500 mg May Delay Time of Disease Progression Over 250-mg Dose in Postmenopausal Women With Hormone Receptor-Positive Advanced Breast Cancer 6Onyx Pharmaceuticals to Webcast Analyst Briefing on Development Program 2Tim McGraw and Faith Hill Join Senior Military for Country United 3A Advancing Medicine From the Frontlines to the Homefront 47536 1Tim McGraw and Faith Hill Join Senior Military for Country United 3A Advancing Medicine From the Frontlines to the Homefront 47536 2Tim McGraw and Faith Hill Join Senior Military for Country United 3A Advancing Medicine From the Frontlines to the Homefront 47536 3New Market Research Study Shows Lung Cancer Treatments Differ Significantly by Both Age and Geography 47533 1New Market Research Study Shows Lung Cancer Treatments Differ Significantly by Both Age and Geography 47533 2New Market Research Study Shows Lung Cancer Treatments Differ Significantly by Both Age and Geography 47533 3Viewers Beware Report by Watchdog Group Exposes Conservative Group Behind Anti Healthcare Ads Running in Montana 47530 1Viewers Beware Report by Watchdog Group Exposes Conservative Group Behind Anti Healthcare Ads Running in Montana 47530 2